Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Survival rates for bladder cancer in UK are falling, confirms new study

Of the top 10 cancers in the UK, bladder cancer is only one where survival rates have been shown to be getting worse. New figures published this month in the Journal of Clinical Urology confirm in a study of cases of bladder cancer in England over a 19 year period (from 1990 until 2009) that survival rates here in the UK are falling and are worse than in than in other European countries with similar incidence rates.

27 Feb 2014

Scientists discover how viral DNA of HBV can be degraded in cell nucleus

Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.

24 Feb 2014

UT Southwestern receives grant to establish Center for Patient-Centered Outcomes Research

UT Southwestern Medical Center has been funded to establish a Center for Patient-Centered Outcomes Research that supports and conducts high-quality research comparing the outcomes and effectiveness of different strategies to prevent, diagnose, treat, and monitor health conditions to improve patient care.

18 Feb 2014

Study findings suggest potential targets for treating HCV

The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to the virus' attempt to weaken the attack on it.

11 Feb 2014

Alabama experts develop living document that includes new therapies for Hepatitis C virus

When treatment guidelines for a particular disease emerge, they are often published in a peer-reviewed medical journal, which can take up to three years. One University of Alabama at Birmingham infectious diseases expert recently helped develop new Hepatitis C virus (HCV) guidelines that can be updated and published as new data emerge and new therapies are approved.

5 Feb 2014

Vodka contributes to high death rates in Russia, new study confirms

The high and sharply fluctuating death rates in Russia are due mainly to alcohol, particularly vodka, a new prospective study of 151 000 adults confirms.

3 Feb 2014

Researchers find liver tumors in mice exposed to BPA during gestation and nursing

In one of the first studies to show a significant association between BPA and cancer development, University of Michigan School of Public Health researchers have found liver tumors in mice exposed to the chemical via their mothers during gestation and nursing.

3 Feb 2014

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.

31 Jan 2014

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

30 Jan 2014

Surgeon general: Smoking linked to more than 30 diseases, conditions

The report, which finds that smoking causes even more physical and financial damage than previously estimated, was released 50 years after the first report tied cigarettes to diseases.

20 Jan 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

First Edition: January 17, 2014

Today's headlines include reports from Capitol Hill about passage of a $1.1 billion spending bill as well as testimony by an Obama administration official about healthcare.gov

17 Jan 2014

Monitoring individuals with chronic HBV is cost-effective strategy for China

A novel study determined that monitoring inactive chronic hepatitis B (HBV) carriers is a cost-effective strategy for China. However, results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that increasing treatment, monitoring and adherence to therapy are necessary to achieve significant health benefits at the population level.

16 Jan 2014

New drug combination proves effective in treatment of hepatitis C

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.

16 Jan 2014

Research: SLPI protein produced by body in response to injury plays vital role in patients with ALF

Findings published in the American Association for the Study of Liver Diseases journal, Hepatology, indicate that infection, the commonest cause of mortality in patients with acute liver failure, may be decreased by inhibiting the activity of a protein found in saliva called SLPI.

10 Jan 2014

Blueprint Medicines closes $25 million Series B financing

Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.

7 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

Obesity, alcoholism, and chronic hepatitis all increase the risk of getting liver cancer, which is the third leading cause of cancer death worldwide. Obesity in particular is driving a significant increase in liver cancer in the United States.

20 Dec 2013

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma, the most common type of liver cancer.

16 Dec 2013

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013